Upstream Bio Stock
HealthTechLooking to sell Upstream Bio stock or options?
Upstream Bio Inc, a clinical-stage biotechnology company, is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Its lead product, verekitug, is an antagonist in clinical development targeting the receptor for Thymic Stromal Lymphopoietin (TSLP). This cytokine is a validated driver of inflammatory responses and impacts various immune-mediated diseases by acting upstream of multiple signaling pathways.
Maruho, Access Biotechnology, Bain Capital Life Sciences, Samsara BioCapital, Wellington Management, HBM Partners, TCG Crossover Management, Altshuler Shaham Investment House, OrbiMed, Enavate Sciences, HBM Healthcare Investments, Venrock, Omega Funds, Decheng Capital.